Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study

Title:	Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study
Authors:	Ustianowski, Andrew^Aff1; Levin, Myron J.^Aff2; De Wit, Stephane^Aff3; Launay, Odile^{Aff4, Aff5, Aff6}; Veekmans, Bernard^Aff7; Rampling, Tommy^Aff8; Sullivan, James G.^Aff9; Vishnepolsky, Mark^{Aff10, Aff11}; Wijewardane, Priyantha^Aff12; Fawadleh, Yousef^Aff13; Zhang, Huixia^Aff14; Li, Meng^Aff14; Wickramarachchi, Dilki^Aff14; Sharbaugh, Audrey^Aff15; Beavon, Rohini^Aff16; Thissen, Jesse^Aff16; Hirao, Lauren^Aff17; Dzutseva, Vitalina^Aff17; Seegobin, Seth^Aff16; Streicher, Katie^Aff17; Kiazand, Alexandre^Aff18; Esser, Mark T.^Aff17; Chang, Lee-Jah^Aff17; Perez, John L.^Aff17; Cohen, Taylor S.^{Aff17, IDs4026102501515x_cor1}
Source:	Clinical Drug Investigation. 46(2):207-219
Database:	Springer Nature Journals